This goes in agreement with other researches which revealed that despite developments in surgical methods, cytotoxic chemotherapy, and targeting agents against estrogen receptor and HER2, a subset of patients with advanced-stage invasive ductal carcinoma display poor prognosis and early metastasis after single or combination treatment. Here, ERBB2 is linked to invasive ductal breast carcinoma.